The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy
Abstract
BACKGROUND: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. METHODS: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients with bipolar disorder (n = 344), manic or mixed episode, who were inadequately responsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy (olanzapine + mood-stabilizer) or monotherapy (placebo + mood-stabilizer). RESULTS: Olanzapine cotherapy improved patients' YMRS total scores significantly more than monotherapy (-13.11 vs -9.10; P = .003). Clinical response rates (> or = 50% improvement on YMRS) were significantly higher with cotherapy (67.7% vs 44.7%; P< .001). Olanzapine cotherapy improved 21-item Hamilton Depression Rating Scale (HAMD-21) total scores significantly more than monotherapy (4.98 vs 0.89 points; P< .001). In patients with mixed-episodes with moderate to severe depressive symptoms (DSM-IV mixed episode; HAMD-21 score of > or = 20 at baseline), olanzapine cotherapy improved HAMD-21 scores by 10.31 points compared with 1.57 for monotherapy (P< .001). Extrapyramidal symptoms (Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale) were not significantly changed from baseline to end point in either treatment group. Treatment-emergent symptoms that were significantly higher for the olanzapine cotherapy group included somnolence, dry mouth, weight gain, increased appetite, tremor, and slurred speech. CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1976) · Medical Entomology and Zoology · Cited by 8,899
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationTohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Self-citationCarbamazepine in manic-depressive illness: a new treatment
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.7.782 · Cited by 484
The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.
Sachs, G. S., PRINTZ, D. J., Kahn, D. A., Carpenter, D. P., & Docherty, J. P. (2000) · PubMed · Cited by 390
Self-citation
Cited by
Haro, J. M., Kamath, S. A., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.5.x · Cited by 656
Drug effects on salivary glands: dry mouth
Scully CBE, C. (2003) · Oral Diseases · doi:10.1034/j.1601-0825.2003.03967.x · Cited by 472
Potential Mechanisms of Action of Lithium in Bipolar Disorder: Current Understanding
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0039-0 · Cited by 453
DELBELLO, M. P., SCHWIERS, M. L., ROSENBERG, H. L., & STRAKOWSKI, S. M. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00011 · Cited by 443
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Self-citationSuicidal Behaviour in Bipolar Disorder: Risk and Prevention
Tondo, L., Isacsson, G., & Baldessarini, R. J. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00003 · Cited by 402
Goodwin, G. M. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017002003 · Cited by 390
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Tremolizzo, L., Carboni, G., Ruzicka, W. B., Mitchell, C. P., Sugaya, I., Tueting, P., Sharma, R., Grayson, D. R., Costa, E., & Guidotti, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262658999 · Cited by 384
Bowden, C. L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Vågerö, M., & Svensson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0116 · Cited by 376
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationSuppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Self-citationTohen, M., Chengappa, K. N. R., Suppes, T., Baker, R. W., Zarate, C. A., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Ghaemi, S. N., Feldman, P. D., et al. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.4.337 · Cited by 326
Self-citationVersión española de una escala de evaluación de la manía: validez y fiabilidad de la Escala de Young
Colom, F., Vieta, E., Martínez-Arán, A., Garcia-Garcia, M., Reinares, M., Torrent, C., Goikolea, J. M., Banús, S., & Salamero, M. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)73419-2 · Cited by 290
A dverse D rug R eactions in the O rofacial R egion
Scully, C., & Bagan, J.-V. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500405 · Cited by 254
Yatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248
Scherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243
Perlis, R. H., Welge, J. A., Vornik, L. A., Hirschfeld, R. M. A., & Keck, P. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0401 · Cited by 196
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
Self-citationCruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121
Polytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91
Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder (2004) · Australian and New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01356.x · Cited by 90
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“Olanzapine has the highest number of published randomized control trials (RCTs) [1,60,85,87,108-128] and a solid basis supporting its use in bipolar disorder [129],”
Al Jurdi, R. K., Marangell, L. B., Petersen, N. J., Martinez, M., Gyulai, L., & Sajatovic, M. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318187135f · Cited by 72
Treatment of mixed bipolar states
Fountoulakis, K. N., Kontis, D., Gonda, X., Siamouli, M., & Yatham, L. N. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001817 · Cited by 68
Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0197-8 · Cited by 66
Combination Therapy for Manic Phases: A Critical Review of a Common Practice
Geoffroy, P. A., Etain, B., Henry, C., & Bellivier, F. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12017 · Cited by 47
“profiles; Table 3 provides an overview of RCT reporting safety and tolerability data for various combinations [21-25,29,30,34,41,42,44,45,48].”
BackgroundMuralidharan, K., Ali, M., Silveira, L. E., Bond, D. J., Fountoulakis, K. N., Lam, R. W., & Yatham, L. N. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.032 · Cited by 47
Calabrese, F., Luoni, A., Guidotti, G., Racagni, G., Fumagalli, F., & Riva, M. A. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2900-0 · Cited by 43
Bourin, M. S., Severus, E., Schronen, J. P., Gass, P., Szamosi, J., Eriksson, H., & Chandrashekar, H. (2014) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0014-9 · Cited by 40
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Rao (2008) · doi:10.1016/j.pnpbp.2008.05.013 · Cited by 32
Pharmacological treatment of mixed states
Cuomo, A., Nikolova, V. L., Yalin, N., Arnone, D., Fagiolini, A., & Young, A. H. (2017) · CNS Spectrums · doi:10.1017/s1092852917000013 · Cited by 14
Metadata
- Authors
- Tohen, M., Chengappa, K. N. R., Suppes, T., Zarate, C. A., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., Keeter, E. L., Feldman, P. D., Tollefson, G. D., & Breier, A.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-01-01
- Volume
- 59
- Issue
- 1
- Pages
- 62
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2090784587
- Cited by
- 463
- References
- 21
- FWCI
- 25.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.